Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD Gene Editing Therapy
Precision BioSciences announced FDA Fast Track designation for PBGENE-DMD, a first-in-class gene editing therapy for Duchenne muscular dystrophy targeting mutations in exons 45-55, representing up to 60% of DMD patients.